These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 36781556)
1. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer. Choo J; Kua LF; Soe MY; Asuncion BR; Tan BKJ; Teo CB; Tay RYK; So J; Shabbir A; Guowei K; Tan HL; Chan G; Ma H; Ramachandran GK; Lum JHY; Chee CE; Sridharan S; Tan P; Sundar R; Yong WP Gastric Cancer; 2023 May; 26(3):393-404. PubMed ID: 36781556 [TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis. Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer. Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K Oncology; 2020; 98(7):501-511. PubMed ID: 32380498 [TBL] [Abstract][Full Text] [Related]
5. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317 [TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes. Noh BJ; Kim JH; Eom DW Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038 [TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma. Bi Y; Ge L; Ren X; Pang J; Zhao Y; Liang Z Clin Transl Oncol; 2022 May; 24(5):941-949. PubMed ID: 35064455 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750 [TBL] [Abstract][Full Text] [Related]
10. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891 [TBL] [Abstract][Full Text] [Related]
12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression. Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356 [TBL] [Abstract][Full Text] [Related]
14. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695 [TBL] [Abstract][Full Text] [Related]
15. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230 [TBL] [Abstract][Full Text] [Related]
17. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705 [TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485 [TBL] [Abstract][Full Text] [Related]
19. Differential prognostic impact of CD8 Kwak Y; Koh J; Park Y; Hong YJ; Park KU; Kim HH; Park DJ; Ahn SH; Kim WH; Lee HS Br J Cancer; 2020 Apr; 122(9):1399-1408. PubMed ID: 32203213 [TBL] [Abstract][Full Text] [Related]
20. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]